| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
Viral DNA polymerase; HCV NS5B polymerase. Arabinosylhypoxanthine selectively inhibits viral DNA synthesis. It targets the NS5B polymerase in hepatitis C virus. As a purine nucleoside analog, it is incorporated into viral DNA, disrupting its synthesis. The anticancer mechanism relies on inhibiting DNA synthesis and inducing apoptosis.
|
|---|---|
| ln Vitro |
Arabinosylhypoxanthine demonstrates significant anti-herpes simplex virus (HSV) activity. It inhibits HCV NS5B polymerase. As a purine nucleoside analog, it has broad antitumor activity targeting indolent lymphoid malignancies. The compound selectively inhibits viral DNA synthesis.
|
| ln Vivo |
Arabinosylhypoxanthine has shown potential in treating viral infections like HIV, with ongoing research exploring its efficacy and safety profiles. It exhibits antiviral properties against retroviruses in vivo. As a purine nucleoside analog, it would be expected to have antitumor activity in animal models of lymphoid malignancies.
|
| Enzyme Assay |
In vitro antiviral assays involve treating virus-infected cells (e.g., HSV-infected or HCV-infected cells) with Arabinosylhypoxanthine at varying concentrations. Viral DNA synthesis is measured by qPCR or radiolabeled incorporation. NS5B polymerase inhibition is assessed using recombinant enzyme assays. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cells (e.g., virus-infected cells or cancer cell lines) are cultured and treated with Arabinosylhypoxanthine at concentrations typically ranging from 0.1–100 μM for 24–72 hours. Viral replication is measured by qPCR or plaque assays. DNA synthesis inhibition is measured by BrdU incorporation. Cell viability is assessed by standard assays.
|
| Animal Protocol |
In vivo animal studies for Arabinosylhypoxanthine have been conducted in models of viral infections, including retrovirus models. The compound is administered via appropriate routes. Viral load, survival, and toxicity are evaluated. Standard protocols for antiviral nucleoside analog studies in mice are used.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Arabinosylhypoxanthine have not been extensively published. The compound has a molecular weight of 268.23 and formula C10H12N4O5. As a nucleoside analog, it is expected to be taken up by cells via nucleoside transporters and phosphorylated intracellularly.
|
| Toxicity/Toxicokinetics |
Toxicology data for Arabinosylhypoxanthine are limited. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been published. Standard safety precautions should be observed.
|
| References | |
| Additional Infomation |
Arabinosylhypoxanthine (CAS: 7013-16-3, molecular formula C10H12N4O5, molecular weight 268.23) is a purine nucleoside analog. It selectively inhibits viral DNA synthesis and has anti-HSV and anti-HCV activity. It exhibits antiviral properties against retroviruses. It is not in clinical trials and has no regulatory approval.
|
| Molecular Formula |
C10H12N4O5
|
|---|---|
| Molecular Weight |
268.23
|
| Exact Mass |
268.081
|
| CAS # |
7013-16-3
|
| PubChem CID |
135410268
|
| Appearance |
White to off-white solid powder
|
| Density |
2.08g/cm3
|
| Boiling Point |
732.8ºC at 760 mmHg
|
| Melting Point |
259-260 °C (lit.)
|
| Flash Point |
397ºC
|
| Index of Refraction |
1.879
|
| LogP |
-1.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
405
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O
|
| InChi Key |
UGQMRVRMYYASKQ-UHTZMRCNSA-N
|
| InChi Code |
InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7+,10-/m1/s1
|
| Chemical Name |
9-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~33.3 mg/mL (~124.3 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (9.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7281 mL | 18.6407 mL | 37.2814 mL | |
| 5 mM | 0.7456 mL | 3.7281 mL | 7.4563 mL | |
| 10 mM | 0.3728 mL | 1.8641 mL | 3.7281 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
